Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with lomitapide and to avoid use in pregnancy

Manufacturers are reinforcing these warnings. Screening for steatohepatitis should be performed before starting and then annually. The absence of pregnancy in women of child bearing potential should be confirmed before starting and effective contraception used whilst on treatment

Source:

Amryt Pharmaceuticals